Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1987 1
1988 1
1989 2
1991 1
1994 2
1995 3
1996 8
1997 6
1998 8
1999 5
2000 8
2001 9
2002 8
2003 11
2004 5
2005 11
2006 14
2007 13
2008 13
2009 15
2010 18
2011 18
2012 21
2013 17
2014 15
2015 13
2016 12
2017 16
2018 17
2019 20
2020 25
2021 30
2022 21
2023 26
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

379 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Challenges of Immune Checkpoint Inhibitors.
de Miguel M, Calvo E. de Miguel M, et al. Cancer Cell. 2020 Sep 14;38(3):326-333. doi: 10.1016/j.ccell.2020.07.004. Epub 2020 Aug 3. Cancer Cell. 2020. PMID: 32750319 Free article. Review.
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Sacher A, et al. Among authors: de miguel m. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. N Engl J Med. 2023. PMID: 37611121 Free article. Clinical Trial.
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Jhaveri K, et al. Among authors: de miguel mj. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18. Ann Oncol. 2023. PMID: 37597578 Free article. Clinical Trial.
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, Golan T, Geva R, Wermke M, de Miguel M, Palcza J, Jha S, Chaney M, Abraham AK, Healy J, Falchook GS. Garralda E, et al. Among authors: de miguel m. ESMO Open. 2022 Dec;7(6):100639. doi: 10.1016/j.esmoop.2022.100639. Epub 2022 Dec 6. ESMO Open. 2022. PMID: 36493599 Free PMC article.
A Mediterranean diet with additional extra virgin olive oil and pistachios reduces the incidence of gestational diabetes mellitus (GDM): A randomized controlled trial: The St. Carlos GDM prevention study.
Assaf-Balut C, García de la Torre N, Durán A, Fuentes M, Bordiú E, Del Valle L, Familiar C, Ortolá A, Jiménez I, Herraiz MA, Izquierdo N, Perez N, Torrejon MJ, Ortega MI, Illana FJ, Runkle I, de Miguel MP, Montañez C, Barabash A, Cuesta M, Rubio MA, Calle-Pascual AL. Assaf-Balut C, et al. Among authors: de miguel mp. PLoS One. 2017 Oct 19;12(10):e0185873. doi: 10.1371/journal.pone.0185873. eCollection 2017. PLoS One. 2017. PMID: 29049303 Free PMC article. Clinical Trial.
Corneal stroma regeneration: Preclinical studies.
Alió Del Barrio JL, Arnalich-Montiel F, De Miguel MP, El Zarif M, Alió JL. Alió Del Barrio JL, et al. Among authors: de miguel mp. Exp Eye Res. 2021 Jan;202:108314. doi: 10.1016/j.exer.2020.108314. Epub 2020 Oct 24. Exp Eye Res. 2021. PMID: 33164825 Review.
T-cell-engaging Therapy for Solid Tumors.
de Miguel M, Umana P, Gomes de Morais AL, Moreno V, Calvo E. de Miguel M, et al. Clin Cancer Res. 2021 Mar 15;27(6):1595-1603. doi: 10.1158/1078-0432.CCR-20-2448. Epub 2020 Oct 20. Clin Cancer Res. 2021. PMID: 33082210 Review.
The future of oncology therapeutics.
Mansinho A, Boni V, de Miguel M, Calvo E. Mansinho A, et al. Among authors: de miguel m. Expert Rev Anticancer Ther. 2017 Jul;17(7):563-565. doi: 10.1080/14737140.2017.1331131. Epub 2017 May 22. Expert Rev Anticancer Ther. 2017. PMID: 28504011 No abstract available.
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmén M, Bono P. Rannikko JH, et al. Among authors: de miguel m. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5. Cell Rep Med. 2023. PMID: 38056464 Free PMC article. Clinical Trial.
Corneal Regeneration Using Adipose-Derived Mesenchymal Stem Cells.
Alió Del Barrio JL, De la Mata A, De Miguel MP, Arnalich-Montiel F, Nieto-Miguel T, El Zarif M, Cadenas-Martín M, López-Paniagua M, Galindo S, Calonge M, Alió JL. Alió Del Barrio JL, et al. Among authors: de miguel mp. Cells. 2022 Aug 16;11(16):2549. doi: 10.3390/cells11162549. Cells. 2022. PMID: 36010626 Free PMC article. Review.
379 results